Collectively, all our findings suggest that CMTM7 is a novel biomarker that can recognize the immune-hot TME and predict the effective therapeutic response of immunotherapy in BRCA, indicating that measuring the CMTM7 levels of breast cancers could guide the therapeutic schedule. This evidence concerns the gene CMTM7 and breast carcinoma.